Q-omics provides the consensus-scored TENT5C profile across patient tissues and cancer cell-line models. TENT5C expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TENT5C is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, TENT5C RNA expression shows 19,288 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, COAD, and THYM as cancer lineages where TENT5C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TENT5C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TENT5C survival associations across molecular data types. TENT5C RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TENT5C RNA expression–survival associations across cancer types. High TENT5C expression shows favorable associations in SKCM, HNSC, KIRC, LUAD, UCEC and MESO. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TENT5C RNA expression.
This table summarizes TENT5C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TENT5C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TENT5C shows lower tumor expression in COAD, THCA, KIRC, KIRP, KICH and BLCA. The COAD box plot shows higher TENT5C RNA expression in normal versus tumor tissue (log2 FC = −2.635, t-test p < 0.001).
This table shows molecular features associated with TENT5C in patient tissues and cancer cell lines. In patient samples, TENT5C shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TENT5C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
